Drilldown: Medicines
Use the filters below to narrow your results.
generic:
brand:
classes: (Click arrow to add another value)
mechanism:
None (4) ·
Active metabolite of tramadol; mu-opioid agonist (1) ·
Butyrophenone D2 antagonist (1) ·
D2 receptor antagonist; also H1, alpha-1, muscarinic antagonist (1) ·
D2/5-HT2A antagonist (1) ·
D2/5-HT2A antagonist; 5-HT7 antagonist (1) ·
D2/5-HT2A antagonist; active metabolite of risperidone (1) ·
D2/5-HT2A antagonist; SRI and NRI (1) ·
Dibenzoxazepine D2/5-HT2 antagonist (1) ·
Dihydroindolone D2 antagonist (1) ·
Diphenylbutylpiperidine D2 antagonist (1) ·
Extremely potent mu-opioid receptor agonist (1) ·
Highly potent mu-opioid receptor agonist (1) ·
Kappa agonist; mu antagonist (1) ·
Kappa agonist; mu partial agonist (1) ·
Kappa agonist; mu partial agonist/antagonist (1) ·
Mitragynine/7-hydroxymitragynine; mu-opioid partial agonist (1) ·
Mu-opioid agonist; modulates glutamate AMPA receptors (1) ·
Mu-opioid agonist; norepinephrine reuptake inhibitor (1) ·
Mu-opioid receptor agonist (4) ·
Mu-opioid receptor agonist; fentanyl analogue (1) ·
Mu-opioid receptor agonist; NMDA antagonist (1) ·
Mu-opioid receptor agonist; prodrug (metabolized to morphine) (1) ·
Mu-opioid receptor agonist; sodium channel blocker (1) ·
Mu/kappa/delta agonist; NMDA antagonist (1) ·
Multi-receptor antagonist (D2, 5-HT2A, H1, alpha) (1) ·
Multi-receptor antagonist; low D2 affinity (1) ·
Opioid receptor partial agonist/antagonist; toxic alkaloid (1) ·
Partial mu-opioid agonist; kappa antagonist (1) ·
Partial mu-opioid receptor agonist; alpha-2 agonist (1) ·
Phenothiazine D2 antagonist (4) ·
Phosphodiesterase inhibitor; calcium channel blocker (1) ·
Potent mu-opioid receptor agonist (6) ·
Prodrug of morphine; mu-opioid receptor agonist (1) ·
Prodrug; converted to [[Morphine|morphine]] by [[Enzyme:CYP2D6|CYP2D6]] for analgesic action. (1) ·
Selective mu-opioid receptor agonist (1) ·
Thioxanthene D2 antagonist (1) ·
Ultra-short-acting mu-opioid agonist (1)
uses:
None (47) ·
Mild to moderate pain; cough suppression (low-dose). (1) ·
'"`UNIQ--vote-000001D9-QINU`"', '"`UNIQ--vote-000001DA-QINU`"', '"`UNIQ--vote-000001DB-QINU`"', '"`UNIQ--vote-000001DC-QINU`"' (1) ·
'"`UNIQ--vote-0000079C-QINU`"', '"`UNIQ--vote-0000079D-QINU`"' (1) ·
'"`UNIQ--vote-0000099F-QINU`"', '"`UNIQ--vote-000009A0-QINU`"', '"`UNIQ--vote-000009A1-QINU`"', '"`UNIQ--vote-000009A2-QINU`"', '"`UNIQ--vote-000009A3-QINU`"', '"`UNIQ--vote-000009A4-QINU`"' (1) ·
'"`UNIQ--vote-00000F98-QINU`"', '"`UNIQ--vote-00000F99-QINU`"', '"`UNIQ--vote-00000F9A-QINU`"', '"`UNIQ--vote-00000F9B-QINU`"' (1)
starting dose:
None (47) ·
Adult: 15–60 mg every 4 hours as needed. (1) ·
Apply a thin film to affected area BID; '''limit to 2 weeks''' continuous use and ≤50 g/week (cream/ointment); ≤50 mL/week (foam/solution); avoid face, intertriginous areas (1) ·
ICS Pulmicort Flexhaler 180-360 mcg BID; intranasal Rhinocort 64 mcg/spray, 1-2 sprays/nostril daily; Entocort EC 9 mg PO daily for active Crohn's; Symbicort 80/4.5 or 160/4.5 mcg, 2 puffs BID (1) ·
Inhaled (Flovent HFA) 88 mcg BID; intranasal (Flonase) 2 sprays/nostril daily; topical (Cutivate) 0.05% cream BID (1) ·
Intranasal Nasonex 2 sprays/nostril daily (50 mcg/spray); inhaled Asmanex 220 mcg DPI 1-2 inhalations daily/BID; topical Elocon 0.1% cream daily (1)
preparations:
None (47) ·
Cream, ointment, lotion, foam, solution, shampoo, spray at 0.025-0.05%; emollient and non-emollient bases (1) ·
Inhaled MDI 44/110/220 mcg per actuation; DPI (Diskus) 50/100/250 mcg; nasal spray 50 mcg/actuation; cream/ointment 0.005%, 0.05% (1) ·
Nasonex 50 mcg/actuation intranasal; Asmanex HFA MDI 100/200 mcg; Asmanex Twisthaler DPI 110/220 mcg; Elocon 0.1% cream/ointment/lotion; Sinuva sinus implant; Dulera (with formoterol) (1) ·
Pulmicort Flexhaler DPI 90, 180 mcg/dose; Pulmicort Respules 0.25, 0.5, 1 mg/2 mL nebulized; Rhinocort intranasal 32 mcg/spray; Entocort EC 3 mg capsules; Uceris 9 mg ER tablets and rectal foam (1) ·
Tablet (15, 30, 60 mg); oral solution; combination products (with [[Acetaminophen|acetaminophen]] or ibuprofen). (1)
fda max:
routes:
onset:
None (47) ·
30–60 min (PO) (1) ·
Hours to days for inflammation; substantial improvement within 1 week (1) ·
Inhaled: bronchial effect 1-2 weeks; nasal: symptom relief 12-24 hours; topical: hours (1) ·
Inhaled: bronchial effect 1-2 weeks; oral GI effect 1-2 weeks (1) ·
Intranasal: symptom relief 12-24 hours; inhaled: bronchial effect 1-2 weeks (1)
duration:
halflife:
None (47) ·
2.5–3 hours (1) ·
Not meaningfully described for topical use (systemic exposure varies with surface area, occlusion, skin integrity)'"`UNIQ--ref-0000079E-QINU`"' (1) ·
~2-3.6 hours (plasma)'"`UNIQ--ref-000009A5-QINU`"' (1) ·
~5 hours (plasma)'"`UNIQ--ref-00000F9C-QINU`"' (1) ·
~7.8 hours (fluticasone propionate, inhaled systemic exposure)'"`UNIQ--ref-000001DD-QINU`"' (1)
bioavailability:
None (47) ·
<1% oral (extensive first-pass via CYP3A4); ~30% inhaled lung deposition'"`UNIQ--ref-000001DE-QINU`"' (1) ·
Intranasal: <1% systemic; inhaled lung deposition with extensive first-pass clearance'"`UNIQ--ref-00000F9D-QINU`"' (1) ·
Topical with variable systemic absorption depending on body site, occlusion, and skin integrity; HPA-axis suppression is documented even with brief courses to large areas'"`UNIQ--ref-0000079F-QINU`"' (1) ·
~50% (variable, CYP2D6-dependent for analgesic effect). (1) ·
~6-13% inhaled lung deposition; ~10% oral (Entocort EC; extensive first-pass via CYP3A4 — this is the basis of the favorable hepatic-targeted local-effect profile in IBD)'"`UNIQ--ref-000009A6-QINU`"' (1)
pregnancy:
None (47) ·
Avoid; risk of neonatal opioid withdrawal with chronic use; UM-mother breastfeeding contraindicated. (1) ·
Inhaled and intranasal generally considered safe; widely used in asthma in pregnancy.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Intranasal long considered acceptable; widely used in obstetric rhinitis.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Long the preferred ICS in pregnancy (Pulmicort) due to the most pregnancy data among the class.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1) ·
Topical corticosteroids in pregnancy: use lowest potency and smallest area; super-potent agents like clobetasol are reserved for compelling indications.<sup class="pcp-cn" title="This claim needs a citation.">[[[Pharmacopedia:Citation needed|citation needed]]]</sup> (1)
legal:
None (47) ·
OTC (intranasal Flonase) and [[USLegal:Prescription only|Rx-only]] (inhaled, topical) in US (1) ·
OTC (intranasal Rhinocort Allergy) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
OTC (Nasonex 24HR) and [[USLegal:Prescription only|Rx-only]] (other forms) in US (1) ·
US Schedule II (single-entity); Schedule III–V (combination products by content). (1) ·
[[USLegal:Prescription only|Rx-only]] in US (1)
Showing below up to 52 results in range #1 to #52.
7
A
B
C
D
E
F
H
I
K
L
M
N
O
P
- Paliperidone
- Papaverine
- Pentazocine
- Perphenazine
- Pharmacopedia:Pharmacogenomics sandbox/Codeine
- Pimozide